From: The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer
Classification system | Cases | Pathological response | ||||
---|---|---|---|---|---|---|
NSABP | pCR | 5 | No histological evidence of invasive tumour cells | |||
pINV | 84 | Histological evidence of invasive disease of any extent | ||||
Miller-Payne | G1 | 10 | Some alteration to individual malignant cells but no reduction in overall numbers as compared with the pre-treatment biopsy | |||
G2 | 20 | A minor loss of invasive tumour cells but overall cellularity still high (<30%) | ||||
G3 | 40 | A moderate reduction of in tumour cells up to an estimated 90% loss (30-90%) | ||||
G4 | 14 | A marked disappearance of invasive tumour cells such that only small clusters of widely dispersed cells could be detected (>90%) | ||||
G5 | 5 | No invasive tumours, i.e., only in situ disease or tumour stroma remained | ||||
Sataloff | TA | 20 | Total or near total therapeutic effect | |||
TB | 30 | Subjectively greater than 50 % therapeutic effect but less total and near total | ||||
TC | 29 | Less than 50% therapeutic effect, but effect event | ||||
TD | 10 | No therapeutic effect | ||||
EWGBSP | TR1a | 4 | No residual tumour | |||
TR1b | 1 | No residual invasive tumour but presence of residual in situ carcinoma | ||||
TR2a | 14 | Minimal residual invasive tumour (<10%) | ||||
TR2b | 31 | Therapeutic effect with residual invasive tumour (10-50%) | ||||
TR2c | 29 | Therapeutic effect but >50% residual invasive tumour | ||||
TR3 | 10 | No pathologic response | ||||
CPS-EG | 0 | 0 | Point assignments | |||
1 | 2 | Clinical stage | Pathologic stage | Tumour marker | ||
2 | 19 | I; IIA = 0 | 0; I = 0 | ER negative =1 | G34 =1 | |
3 | 17 | IIB; IIIA = 1 | IIA/B; IIIA/B = 1 | |||
4 | 12 | IIIB; IIIC = 2 | IIIC = 2 | |||
5 | 5 | |||||
6 | 0 |